|1.||Ben Ameur-Mehdi, Raoudha: 1 article (12/2004)|
|2.||Karray-Rebai, Ines: 1 article (12/2004)|
|3.||Bejar, Samir: 1 article (12/2004)|
|4.||Mellouli, Lotfi: 1 article (12/2004)|
|5.||Naili, Belgacem: 1 article (12/2004)|
|6.||Sioud, Samiha: 1 article (12/2004)|
|7.||Yun, B S: 1 article (10/2001)|
|8.||Chung, J M: 1 article (10/2001)|
|9.||Yoo, I D: 1 article (10/2001)|
|10.||Ryoo, I J: 1 article (10/2001)|
|1.||Ganglion Cysts (Ganglion)
12/01/2004 - "The nucleotide sequence of the 16S rRNA gene (1516 bp) of the TN58 strain showed high similarity (96-98%) to the Streptomyces 16S rRNA genes, especially with that of Streptomyces lavendulae which produces the anti-tumor compound mitomycin C, and the cyclic peptide antibiotic, complestatin. "
08/30/1991 - "When MT-4 cells were pretreated with complestatin for 2 hrs prior to the exposure to HIV-1, the HIV-1-induced cytopathicity was markedly inhibited, while pretreatment of HIV-1 with the agent did not affect the infection. "
08/30/1991 - "Complestatin, an anti-complement agent, was shown to be a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) infection in vitro. "
02/01/1989 - "This compound inhibited the hemolysis of sensitized sheep erythrocytes (EA) mediated by guinea pig and human complement 50% at concentrations of 0.4 and 0.7 micrograms/ml, respectively, but did not trypsin and alpha-chymotrypsin activities at 200 micrograms/ml. When complestatin was administered intravenously to the sensitized guinea pigs, it strongly inhibited the systemic anaphylactic shock elicited by the antigen probably by blocking generation of anaphylatoxins (C3a and C5a)."
|1.||Complement System Proteins (Complement)